IDEAS home Printed from https://ideas.repec.org/a/gei/journl/v8y2021i1p36-49.html
   My bibliography  Save this article

Communication for Open Innovation in Japanese Drug Discovery Ventures

Author

Listed:
  • Kenji Tomita

    (Doshisha University)

Abstract

Drug discovery ventures find candidate substances likely to develop into new drugs by selecting and concentrating management resources that specialize in basic and exploratory research and license them to pharmaceutical companies. They conduct R&D activities on the premise of open innovation; however, the number of their licensing cases is small. Therefore, in this study, we conducted a questionnaire survey to find variables that affect the performance of open innovation. Questionnaires were mailed to 349 drug discovery venture companies in Japan (41 addresses unknown), and valid responses were collected from 42 companies (response rate: 13.6%). Using a SEM analysis, we found the importance of communication in open innovation. Communication has direct impact on open innovation and has been found to enhance open innovation through customer orientation. Drug discovery ventures are the ultimate technology-oriented companies, and, while they tend to lower their communication awareness in business negotiations, they must raise their communication awareness to improve the performance of open innovation.

Suggested Citation

  • Kenji Tomita, 2021. "Communication for Open Innovation in Japanese Drug Discovery Ventures," Journal of Management Sciences, Geist Science, Iqra University, Faculty of Business Administration, vol. 8(1), pages 36-49, March.
    • Handle: RePEc:gei:journl:v:8:y:2021:i:1:p:36-49
    as

    Download full text from publisher

    File URL: http://geistscience.com/JMS/Issue1-21/Article8/JMS-2108103.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Felin, Teppo & Zenger, Todd R., 2014. "Closed or open innovation? Problem solving and the governance choice," Research Policy, Elsevier, vol. 43(5), pages 914-925.
    2. Jeffrey H Dyer & Wujin Chu, 2000. "The Determinants of Trust in Supplier-Automaker Relationships in the U.S., Japan and Korea," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 31(2), pages 259-285, June.
    3. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Graziano Salvalai & Marta Maria Sesana & Paolo Dell’Oro & Diletta Brutti, 2023. "Open Innovation for the Construction Sector: Concept Overview and Test Bed Development to Boost Energy-Efficient Solutions," Energies, MDPI, vol. 16(14), pages 1-19, July.
    2. Gregorio Rius-Sorolla & Sofía Estelles-Miguel & Carlos Rueda-Armengot, 2020. "Multivariable Supplier Segmentation in Sustainable Supply Chain Management," Sustainability, MDPI, vol. 12(11), pages 1-16, June.
    3. Holger Patzelt & Dean A. Shepherd, 2009. "Strategic Entrepreneurship at Universities: Academic Entrepreneurs’ Assessment of Policy Programs," Entrepreneurship Theory and Practice, , vol. 33(1), pages 319-340, January.
    4. Patzelt, Holger & zu Knyphausen-Aufseß, Dodo & Fischer, Heiko T., 2009. "Upper echelons and portfolio strategies of venture capital firms," Journal of Business Venturing, Elsevier, vol. 24(6), pages 558-572, November.
    5. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    6. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    7. Tomas J. Philipson & Eric Sun, 2008. "Is the Food And Drug Administration Safe And Effective?," Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
    8. Salgado, Stéphane & Hemonnet-Goujot, Aurelie & Henard, David H. & de Barnier, Virginie, 2020. "The dynamics of innovation contest experience: An integrated framework from the customer’s perspective," Journal of Business Research, Elsevier, vol. 117(C), pages 29-43.
    9. Ming Liu & Sumner LaCroix, 2011. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 201116, University of Hawaii at Manoa, Department of Economics.
    10. Wang, Chun-Ju & Wu, Lei-Yu, 2012. "Team member commitments and start-up competitiveness," Journal of Business Research, Elsevier, vol. 65(5), pages 708-715.
    11. Abe C. Dunn & Lasanthi Fernando & Eli Liebman, 2024. "How Much Are Medical Innovations Worth? A Detailed Analysis Using Cost-Effectiveness Studies," BEA Papers 0132, Bureau of Economic Analysis.
    12. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
    13. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
    14. Waters, James, 2014. "Introduction of innovations during the 2007-8 financial crisis: US companies compared with universities," MPRA Paper 59016, University Library of Munich, Germany.
    15. Wolfgang Hein & Lars Kohlmorgen, 2005. "Global Health Governance: Conflicts on Global Social Rights," HEW 0509001, University Library of Munich, Germany.
    16. Mohamed M. Mostafa, 2023. "A one-hundred-year structural topic modeling analysis of the knowledge structure of international management research," Quality & Quantity: International Journal of Methodology, Springer, vol. 57(4), pages 3905-3935, August.
    17. Saeki, Yasuo & Horak, Sven, 2013. "The role of trust in cultivating relation-specific skills: The case of a multinational automotive supplier in Japan and Germany," Working Papers on East Asian Studies 95/2013, University of Duisburg-Essen, Institute of East Asian Studies IN-EAST.
    18. Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
    19. Philipson Tomas J. & Sun Eric & Goldman Dana & Jena Anupam B., 2012. "A Reexamination of the Costs of Medical R&D Regulation," Forum for Health Economics & Policy, De Gruyter, vol. 15(1), pages 1-28, October.
    20. Scherer, F. M., 2007. "Pharmaceutical Innovation," Working Paper Series rwp07-004, Harvard University, John F. Kennedy School of Government.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gei:journl:v:8:y:2021:i:1:p:36-49. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Imtiaz ARIF (email available below). General contact details of provider: https://geistscience.com/JMS/index.php .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.